Dr. Francisco Mera Cordero
Francisco Mera Cordero, M.D. is the Director of the Longevity and Lifestyle Medicine Unit at Blue Healthcare and the Director of the Precision Medicine Unit for Long COVID and Post-viral Syndromes at the same institution. With over 20 years of experience in family medicine and clinical research, Francisco has emerged as a leading expert in Long COVID treatment and post-viral syndrome management.
He serves as the Head of Medical Innovation & Research in Environmental Medicine and Long COVID at Findspo, and holds an advisory position on the International Advisory Council at Universidad San Ignacio de Loyola. He is also the Founding President of CIRLONGCOVID (Centro de Investigación y Difusión del COVID Persistente), demonstrating his commitment to advancing research and education about persistent COVID conditions.
Francisco is the Principal Investigator of the groundbreaking E-SPERANZA COVID-19 clinical trial, a phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy of montelukast for treating mild to moderate respiratory symptoms in Long COVID patients.
This pioneering research, registered as ClinicalTrials.gov NCT04695704, represents one of the first systematic approaches to developing evidence-based treatments for Long COVID. In May 2020, Francisco conducted a successful pilot study using montelukast in 12 patients with Long COVID, all of whom showed clinical improvement within days of treatment. Read Effectiveness of Montelukast against Exuberant Immune Activation in “Long Covid”.
He is the author of the National Guide of the Spanish Society of General and Family Physicians on Persistent COVID and has published extensively on post-viral syndromes and COVID-19 persistence mechanisms. Read Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID.
At Blue Healthcare, Francisco leads comprehensive treatment programs that integrate precision medicine approaches with innovative therapies. His work encompasses diagnosis and treatment of post-viral syndromes, particularly Long COVID or persistent COVID, utilizing advanced interventions including intravenous serotherapy, transcranial magnetic stimulation, and personalized nutraceutical formulations.
He has developed molecular endotyping protocols for Long COVID patients, identifying biomarkers of the encephalo-hepato-pulmonary axis damage and testing clinical and biological improvements with treatments like VITAMIC BIOSEN. His research on the VITAMIC study demonstrated significant improvements in dyspnea, pain, brain fog, digestive symptoms, neuropsychiatric disorders, and sleep disturbances in Long COVID patients.
Francisco has been a member of the CIBER POST COVID working group at Instituto Carlos III since December 2021, contributing to Spain’s national research efforts on post-COVID conditions. He serves as a Vocal member of REICOP (Red Española de Investigación COVID), the Spanish Research Network for COVID investigation, where he collaborates with leading researchers across the country.
Since 2018, he has been a Rising Star member of the redGDPS Foundation, focusing on diabetes management in primary care. He is also an editorial committee member for El Telemedicina, a digital health publication, and maintains a health dissemination channel dedicated to persistent COVID on Medicina TV.
Francisco’s extensive career with the Institut Català de la Salut spanned from 2002 to 2022, where he served as a family medicine physician and held multiple leadership positions. During this time, he was the Medical Investigator of the Research Support Unit at DAP Costa Ponent from June 2020 to April 2022, leading the ESPERANZA COVID-19 project. He served as an accredited tutor for medical residents in family medicine and collaborated as a teaching physician at the Universitat Autònoma de Barcelona from February 2020 to April 2022. His roles included membership in the Functional Post-COVID Unit Expert Committee of the Territorial Management Metropolitana SUD Barcelona and Adjunct Director at EAP Vallirana from April 2016 to August 2018.
Francisco earned his Medical Degree (Licenciatura in Medicine and General Surgery) from the Universidad de Zaragoza in 2001, where he studied from 1995 to 2001. He completed his specialization in Family Medicine at the Institut Català de la Salut from 2002 to 2005, obtaining his MD certification. Between 2018 and 2020, he earned his Master’s degree in Diabetology from the Universidad Francisco de Vitoria, further specializing in metabolic disorders and their relationship with chronic conditions.
Francisco currently serves on multiple advisory boards and professional organizations. He has been a member of the International Advisory Council at Universidad San Ignacio de Loyola since April 2023, providing expertise on medical education and research initiatives. He is actively involved with Doctoralia España and Top Doctors, offering telemedicine consultations for COVID-19, longevity medicine, diabetes risk assessment, and cardiovascular disease management. Since January 2012, he has been a teaching professor at Educación Continuada Sanitaria (Educsa), contributing to continuing medical education programs.
In recognition of his contributions to COVID-19 research, Francisco received the ICI grant from the Instituto de Investigación Carlos III ISCIII in July 2021 for the ESPERANZA COVID project. In September 2022, he was awarded the Best Communication in Primary Care award from the Baix Llobregat division of the Official College of Physicians of Barcelona for his study Esperanza COVID. His research has been featured in numerous peer-reviewed publications, including studies on the prion hypothesis in Long COVID and the effectiveness of psychological interventions for persistent COVID symptoms.
Francisco has established himself as a thought leader in Long COVID research, frequently appearing at international conferences and contributing to public discourse on post-viral syndromes. His expertise extends to environmental medicine, longevity medicine, and the development of precision medicine approaches for chronic conditions.
He has developed innovative treatment protocols combining conventional medicine with advanced therapeutic modalities, including the use of omics tools and artificial intelligence for personalized medicine applications. Read The Prion hypothesis about Long Covid and SARS-CoV-2 and Effectiveness of Montelukast against Exuberant Immune Activation in “Long Covid”.
Francisco lives in Madrid, Spain, where he continues his clinical practice and research activities. He maintains active profiles on professional networks and regularly shares research updates and clinical insights with the medical community. His work has been instrumental in advancing understanding of Long COVID pathophysiology and developing practical treatment approaches for patients suffering from persistent post-viral symptoms. Watch VITAMIC BIOSEN – TRIAL AND BIOMARKER RESULTS – FIGHT #longcovid.
Visit his LinkedIn profile, Doctoralia profile, ResearchGate profile, and Top Doctors profile. Follow him on Facebook, Instagram, the Org, and X.